ArticleCell2018
Evolutionary Pressure against MHC Class II Binding Cancer Mutations.
Erratum issuedAbstract read
In one paragraph
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 128 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Traditional Chinese medicines and capecitabine-based chemotherapy for colorectal cancer treatment: A meta-analysis.Cancer medicine · 2023Pooled it
- Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.Annals of oncology : official journal of the European Society for Medical Oncology · 2020Pooled it
- UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.Cell reports. Medicine · 2025Trial
- Cancer epitope prediction tools and analysis pipelines in CEDAR.Nucleic acids research · 2026Article
- Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis.bioRxiv : the preprint server for biology · 2026Article
- No evidence of immunosurveillance in mutation-hotspot-driven clonal hematopoiesis.Nature genetics · 2026Article
- Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond.Journal of immunotherapy and precision oncology · 2026Review
- High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant.Nature communications · 2026Article
- Rare variable M. tuberculosis antigens induce predominant Th17 responses in human infection.JCI insight · 2026Article
- HLA Heterozygosity Influences Colorectal Cancer Risk and Survival Outcome.Gastroenterology · 2026Article
- Article
- Integrating Three Functional Subsets of T Cell Immunity Into an Integrative Model for Cancer Immunotherapy.Immune network · 2026Review
- Human Leukocyte Antigen (HLA) and Tumor Immunity: A Critical Link in Cancer Immunotherapy.Immunity, inflammation and disease · 2026Review
- NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes.Nature communications · 2026Article
- Computational Methods for Cancer Neoantigen Prediction.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma.Cancer communications (London, England) · 2026Article
- Small cell lung cancer: relationship with HLA-I alleles and gene mutation.Journal of cardiothoracic surgery · 2025Article
- Transcriptome Analysis Unravels CD4Biomolecules · 2025Article
- NeoPrecis: Enhancing Immunotherapy Response Prediction through Integration of Qualified Immunogenicity and Clonality-Aware Neoantigen Landscapes.bioRxiv : the preprint server for biology · 2025Article
- A vaccine targeting lung resident-memory CD4NPJ vaccines · 2025Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Rachel Marty PykeDepartment of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA 92093, USA.
Wesley Kurt ThompsonDepartment of Family Medicine and Public Health, Division of Biostatistics & Bioinformatics, University of California San Diego, La Jolla, CA 92093, USA.
Rany M SalemDepartment of Family Medicine and Public Health, University of California San Diego, La Jolla, CA 92093, USA.
Joan Font-BurgadaDepartment of Pharmacology, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Cancer Biology Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Maurizio ZanettiMoores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA; The Laboratory of Immunology and Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Hannah CarterDepartment of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA; CIFAR, MaRS Centre, West Tower, 661 University Ave., Suite 505, Toronto, ON, Canada. Electronic address: hkcarter@ucsd.edu.
Funding
TR&D 3 - Network Guided Machine LearningP41GM103504 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BADER, GARY D. · 2012 to 2024
$17.3MNetwork approaches to identify cancer drivers from high-dimensional tumor dataDP5OD017937 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARTER, HANNAH KATHRYN · 2013 to 2017
$1.9MPolygenicity, Pleiotrophy and Power: Novel Statistical Methods for Gene DiscoveryR01GM104400 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI THOMPSON, WESLEY KURT · 2014 to 2017
$1.6M(PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expressionR01CA220009 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARTER, HANNAH KATHRYN, ZANETTI, MAURIZIO · 2017 to 2021
$1.5MDevelopment of mosaic mouse models of HCC for genetic interspecies inferenceR00CA191152 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI FONT-BURGADA, JOAN · 2017 to 2019
$747kMethods for Genetic Association Analysis of Longitudinal and Multiple PhenotypesR00HL122515 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SALEM, RANY · 2017 to 2019
$732kMethods for Genetic Association Analysis of Longitudinal and Multiple PhenotypesK99HL122515 · NHLBI · BROAD INSTITUTE, INC. · PI SALEM, RANY · 2014 to 2015
$264kDevelopment of mosaic mouse models of HCC for genetic interspecies inferenceK99CA191152 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FONT-BURGADA, JOAN · 2015 to 2016
$219kNCI NIH HHS K99 CA191152NCI NIH HHS R00 CA191152NCI NIH HHS R01 CA220009NHLBI NIH HHS K99 HL122515NHLBI NIH HHS R00 HL122515NIGMS NIH HHS P41 GM103504NIGMS NIH HHS R01 GM104400NIH HHS DP5 OD017937
Abstract
The anti-cancer immune response against mutated peptides of potential immunological relevance (neoantigens) is primarily attributed to MHC-I-restricted cytotoxic CD8
Indexed as
Age FactorsAnimalsAntigens, NeoplasmCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesEvolution, MolecularHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHumansImmunotherapyMutationNeoplasmsAntigens, NeoplasmHistocompatibility Antigens Class IHistocompatibility Antigens Class IIcancerdriver mutationsimmune editingimmunityimmunotherapyMHC-IIT cellstumor evolution
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.